Thank you for attending THSNA 2026. The virtual meeting is now closed.
Use this page to browse all contributing authors.
Presentations for Sophie Susen
Recombinant von Willebrand Factor Prophylaxis for Severe von Willebrand Disease: Final Results Focusing on Adults Receiving Once Weekly Prophylaxis in a Phase 3b Continuation Study |
From Efficacy to Experience: 52-Week Patient-Reported Outcomes with Mim8 in Adolescents and Adults with Hemophilia A with or without Inhibitors (FRONTIER2) |